PT  - JOURNAL ARTICLE
AU  - Hannah Walton
AU  - Samantha Hopkins
AU  - Alan Shand
AU  - Shahida Din
TI  - Immunotherapy-induced coeliac disease in curative lung cancer
AID  - 10.1136/bcr-2021-243406
DP  - 2021 Sep 01
TA  - BMJ Case Reports
PG  - e243406
VI  - 14
IP  - 9
4099  - http://casereports.bmj.com/content/14/9/e243406.short
4100  - http://casereports.bmj.com/content/14/9/e243406.full
SO  - BMJ Case Reports2021 Sep 01; 14
AB  - The advent of immunotherapy has revolutionised the treatment of metastatic lung cancer and it has recently been established as the standard of care in the radical treatment of lung cancer. However, immune-related adverse events (IrAEs) frequently occur in patients treated with immunotherapy, and rare IrAEs continue to be identified. We report a case of immunotherapy-induced coeliac disease due to adjuvant durvalumab post-chemoradiotherapy in a patient receiving curative treatment for lung cancer. The patient had raised anti-tissue transglutaminase IgA and histological findings consistent with coeliac disease. This is the first published case report of probable immunotherapy-induced coeliac disease both with the immunotherapy drug durvalumab and in the curative lung cancer setting.